Bee 2 es Lgl ES at ee me eed Cre ee seAss tN Fi =m Hee HOR BRR ( KE HIP) BWM Warne Lt Ea Eo PL PIL pea RE HA ERE PRERIES eP me LE Te iE At Ak HEH Se Bi HAT BE AKL ERBRBena (CIP) BGR PS ae ae TP / 79 {AMEE 2013 ISBN 978-7-117-17130-4 L.O”- I. Oe Ul. OA AAR bat: ABST: ei Pat 1 RL WAS Ls FY CIP BAAR F (2013) 38 066599 ADEA wow. pmph. com HARE, ARNO ALESHA www. ipmph.com BFSntHS, BAM BERS, BERR i, AACR ATA AULA, BAL! ABS REN FS A 2 TT RR WIS T: APRA HH AGEL CP ARR 010- 59780011) 2 ACCT WB DCH He TE 19 100021 : pmph @ pmph, com WHIRL: 010-59787592 010-59787581 010- 65261830 Fl Rl: Ate ALE BSB: BARAT FE AK: 7101000 1/16 —-EPAK: 9 FM 171 TF RRR: 2013 4S VFL AR 2013 4 5 AE 1 MS 1 EN) #RHEBS: ISBN 978-7-117-17130-4/R + 17131 tt: 65.0076 FT ay BEARER BAR: 010- 59787491 E- ONLI EDR Hic Fe AS LT WQ @ pmph. com FP LR RO(eA HEME AN Bei PSE EAL: 1989 432 be] FDA TESCHIE ME A 8) TRE BE (Botox) Wilh PRM LY «1993 AF-$ bel Pe] AS sh FPA EST A UP aA AE MD BRITT Fes BEE IUIK BaEAPS Be UL SY AHA. Ce Ma FET 27S eT I AL FD PASE LT A ST SIDI TCE OTHE AR VA PSH IP IRGSEL IRE TG AG 1 A A SAS Be ES AVS EARS eM RESCH AS. ARETE AS APSE A WE AS 5 NT STAT I WY PR IBG BNI ARC aE MY 2 A BB A LI «RBS, SER BE TE: TE, EPR M SARL DG TT 5 TE Py ae ae OY AB AED IAATE He As E. fyi EAS J Et AS SI A HE II Do dO BE EE ay A SE SE ATE BDF PDEA 5 YI FS GI SA Fei SIAN 6) Bae ENT HE» Ae A PF VAHL Ad BV BES YC SF FRAT A IPE EA KIS HEB SHR 5 BALE A LL EY PSO AMAL: 8S EIT CAR HEA PIE 5 VAS SE BES LAS TAD (2 LS fd 6 TLE ed TAIRA 5 HR] — PET RY AM TOY fe eT FE HS SN 1 A ET) DP AAS BRO TRAP LEC i REL BY BS UTI PRIN SARIS ESE ATNLME EA. BS AE EARLE SIE AE SIAN BN EAE STAT AL AIF AUS OR TEAR SAS AH PS ae EM AC HP ERD IED 5 BATE ATT A AS TE Ag Be AE ME IM. ALR APT 19 BL Eee SOE Td a BRR EAT LAB 4D A EP BE BRE BX MOB 2013 4 3 FALSEEisx | CONTENTS B-B AMMBNMIEREHAL - B— PD AAR AEST ABIL A REBAR 8 » URAL « : 5 BULA > FURL PO. GUE PO. HEPES A HIM MMELEREHAK SH HBBALH BLOM BENDR o-- ; oe! BIG RBOASH MEME RRA pl —- : coal BE PBIUL KG J Bic tee2 Lille S=R LREMEREHAE - BD LR AEN OMe RAR —. JTL =. RL = WL Po. RS WLAL SERA REAVER AD a fl 46 + 46 47 60 - a scone 62 66 » BS Sy i HE EG LOE SOR TREMERERHAK SB RAR FE AEA SB OAR REBT BR e AUEPB LA > AULA = /NGR DLA > FER ULA BAR AS 5 BS EBS IS WY HE A 5 1G LE TEES BCP EE PAF BRE ULI I BEE Sy ROWER A HE SLR APALHAWREMIERENTE Si Tie . WOR + FS FALE PER WRU EAL BETTI HR 5 SRE PAAR IE, » 72 Aye BE PAREENA * BAR HEME RAHAK Bp ei 101 LULOR - + 101 » RE + 103 105 + 105 + 106 + 106 107 - + 107 =. ABER ENT R + 108 2. AB LIME + 108 DU Ley A os + 109 110) + 1lo “1 2. AS LBW * 11 DSL Balas: © 11 SCH ASSRATHRAS At BOD HEF EER RIT POORL es 118 oY BRAN RET AOA sesceteeecnetee 114 115 me HERE - ee 117 B= CTRMI ASS 118 + CT HEATER RATT PT 119 —. MRI fe A HERE RATT PAL 120 AOD NSBR BMARAEARS 121 HS RAUL HEL PET RS DE AT Ao B95 121 “AVL Pe) #00 Fe Sa SB | SAE ER eevee 122 BAK ASSP TTR ARAMA RADT + 125 MY WR EBERT MS SARK) ae(Al dé # (botulinum toxin, BTX) J G* IR PCE IA HERE HE LE AL PROACH AGE HEM AS Te] 27 ABYC1C2,D.E.P.G UB, AS Te) EY 9 EE 2 iy. FLAT SETA I PY Bs — LA PE Lit. PEL HE BE VA BREIL PH Sk eb AST] 19 SEAN « 5 FE ae PE AOD hl IE THT HEP EL) le «LV AS at aE WZ O-D), Her A RYCBTX-A) BE JIG Rae 5 PAE Ae A A TT TEAL SEITE BUR BTX-A (4: J8) FBR LS A 29 BEL BAG PO ERA FS i i LR WU A HB SY TEAS. 51 ce PARLE TC AAS Z. PB Li HCO) BEL PK GE AU LE HEL SO UL A ae HE BARAK Pn ge BY RTL PTER TAK. By AMAIA AS RE BTX-A SICH SY BLS AR A EE TBR AY «3 HE PUERCO: BE i HS HE i SL id HEH Sh LEP AE. BTX-A WLS HE AT Wei Se A Hic, EA AN RE AG SEAS EY BIX A052 i 2 ids BA) ee id FE «AS FRE HL LAR IE BRE, BTX-A Z. PE EL AG PE R19 BEL EAL Se SPE SEY «ABR IT PS UL PAL HSE SK 1 BE fle EL FG eB SHAE YY HE ke TA 09 Se A RE Ai =F] — LEE SAE a TOY FE AIR PARR AE. . ASSRIH MIE Ee BEAD T° 258 et 0 HS aR ee Jo LTA ke Mic A EH HEL AE AR «01 HH BLO PY AS FL J os AS LAL RIL EAS 5 Be AP ii BRE. 2 TH Vk ik A SoA AS L2G TAIT FCM “A AE FS SZ BE HEEL 8 HE TAIT (48 0-1). #6) fe Te EY Ai Sed OBIE Hi Ee Td HB 2 GE AT GE AR AS a ET HAH RZ MEAN A «YY BX He Bt yBN HF ROL ASBRS TLE AUK fae NOE FRCL A Pa PEELERAL PALI Aa BREA PEE HR IE) FRA WLR AI BEA ES A KEG J RCA CL A 5 BES AS eH A Mb HR BE SFA Jeb B/S BEE ILS J BE CR AR Re HA fi i i Le: FEB IT SAB Be AF BD AE RULES Ahan ah EA WLR 2A) PEEVE HCHERERE HACER BEIT Bs. Bet HE GEERT Awe ne ea ee ABA Ar AE FE LUI ME Be LA EE BDL BBG BPE ‘HE ai BRERA IHL Ae OB DHE AT AA aH HiLeR Ae a 1A —_@___* = (778 ee ‘AP EDR ke P aE BREDAIBL PREIS FIRES Mi IAG AUG BEE HK WERE TE EET HARGIS a ABR ith Bk DAML HE TE Sha: COAB) PRGA BPE RT ARI BENT Awe RAE F BRAS) HF EE AAS AO Oddi $29 WLEEFE ELE BIC eR ite RET th TB He ABLE «ELD fF DE BIE THRE AN AE Rs Heth, EAGT AS SRA AD BELG IE SD BLE FAT AEE HHL 55 Bk Ji HY BE WSR I Be I tb i oh g81BN # =. BREHAMRRE TESS AAD EINEM. — ARAL FAB th » DAR TRIE 26 HBR EH Ha RAV AB LE FEA WLI ACs CHE IE SE PEE BVA TAIT ILI TT HE ACHR AE SEMA ATE RD ILS «ERE AO AREY « DALIT AERIS A A 9 4 fits li ACF 500U Botox) fi °F.) RHE SAT FRE 7° 4 SPE A HEH EEE AAS TIE HEFT SS 25 BHR IE WL 28 ‘tala TESST A rte BL Inc. ; Botox® (Oculinum, All sIrvine,CA) 4U/ng resUK) = 40U/ng : ~ 100~: 10U/ml Is” (RVPUEAAL A AUAIEER 25U/ne 25-~50U/ml Dysport® (Ipsen; Maidenhead. Be NeuroBloc® AK fA JALATF OY BTX AREA ECU Eb, LU fe 18 ~ 20g ba HE SE 9 FUN He AY TESTBED AREY LDS, BULVE b VL A Bei HS HEE OH) WU] «ELS DL SE] OAH I AR AH AST] BEA f° AP] RS 7 Pa WE Hak AS fd PM FM. PA Iy Botox® FMEA Jk Ii AEF EEN FE OY ATER BLY «AS PE Pr SATE HY FAILS LARA Botox® Fit WB SER AK DASA A AS THES TAR a SAT FRA 0 AY AERA THERE «Ane SeP FL ME AS (19 PULL RE (ASE FE. ARE A SU DLR tne Hey AGP RMT AS Be NUL Pd REG A RE ™ A EH LAL BEAT TESS. Sk a PASULPAS 2 a FE SIE SU ZOO Wwe > Jy AS AS BLN «TG PU RCI PA UV] J BE WLME ET FLAC JUL PAS Fy 2s 2 HR 4, SAE AA HE BT GEA HE AMAL Pf HEAR 8 PLA A LA PF EIDE UGE) «Dr TE REIT HEL OSHA ies 2k 5 LIL UU ij SAS AOL TA «GF BE CIV A Reid ag DEAT ME ME A Wik | Be Ae UE FIN ie 06 AT AION A RITA asec, WLLL Fel te HCTF Bek AM BN aE TA PP ULL EE, G ste* 2 By APRA IE WY ULAR MSL AS ETA a AE a 5 A BY At DRE SK fe FAL « ECE TP BR BR EA LA 8 SL 8 DF TE A TEAK at Ey MLS FAULT) HO «A a WL SS LE AT A I IR SIL ASSET i ay BREA BG HP BEL A Bat Be GAS] FAT at BORN — Ab RL SAE EE TIT BE. ABT Bi cay TEBE 3 ~6 NI BA 2G REIL I Ha Ts «OT A AT SBA OT] 2H A, ZEA hs MILT IS DAME AS IT SC, HL SAE AR WE eR 8 2 10 HULDA Bs HE: "PLL, AEE HE NY TAI TA RAAE hh. FBPURFRRW PEG BRUTE SHEE PA RTT TAIT (9 3 IE. PEE TAIT A bs. On TPB UL PS Se a USCA I LE SH IEE EOE I 5 TEL a I IE BE HS TBE. MELISS REIGN FLAY 5 ERECT IN AT a EULA HS ate BRE AL Ay FE I i) A HE ARIE TE HL 009 EH PE ES HTN ALR a HEE TT IH BEE SEWT Ta] AT ABH BUOY AS BE IZ We Be SAT APR. TE REGU TA aE HIE TAIT MAE 9 0 FE A} — Be SE As ik 2 A RA ABR ME ER A TE HE 4 HE HE BRAT TE STAI AS) SB EL POE 8 AE ESD TS AS EA ‘tie. BIX (Ey — Bat IS AS YE BE LE EH «aT NL AP IE Be eH AGE IE TT BENS «TEP PSL ALE ST Botox AYP SBE Ht AOU /kg. — ie BAIT AR 2s BEE BCA LS JF» CEL (AIR A AEA BTX-A TEAS (ede EY PANE UPA ts eB PAZ PE St IL ed a AEB: BL Gitte ) (AE Is WL HE BEG As ZR BTX-A Xf 42 JUL) $8 hs 44 a8 90 eB BBN PEIN AH IF PS WL TA BE SB 2G HE? RS Ee HK OG OB 5 ES TE EE HS HL A Hs SE OB He WILE, Lambert-Eaton $ ee TCA BTX-A FEST EIU ACAD 2 LTA Be Sk SE a Be ABE A LE, FIER WLU SG mF FR Sie Te BE DE PL RAO PTE. TATE PLS A AINE SA TH Pe Pe IST E25 THEA TROL A 2 UL ALE Sk a BAS YE IL a IL, eT ob BN POTCHE NY ARIAS UT ALAS Ae BSE Ae 2 8 PR ILI AS EA CE IL, Fe ELS REA AS SE T S | SPB PEATE AIT 5)MNO _#_ # BX ASS see E OU 5B Hi) 9 ER A, BG BEL AUST 4 erate Sd Neh CRANE ES ULSI APF» MLA BBA Ai Be TZ LA fi 25 A A TESA A A we We ESAT IE a FD «AAR FR FY A UH. AN SEB BEA ETRE AED TG AS GG as 2 OY TPE A DR en SAY ASAT MLAS LS A PAL a a Hh PG Hy 5 BE FAVRE ATE ITY FALE il O40 eR KAP ASP CE» SB ipeilenemaniaaadianinig FESR» IMIS DH UO HL TATE a = = FE 28 Th CRE ASAE DD PRE BR AP SNE EDV BK SZ TEN PA HP i UT Be (IRE RHE PAL A BBR URL EE AS IT SA LAE SRE IE «DTA a AR SG HR 1 7 AP SAY AP HC AE 5 CE A OD He SE VAG aE RE A Aya Re BUCA. SiCAACHE aM BE — fe SL RE AC Te AT 9 IZ a I AS > SYS AS AF ATOR «TEBE I AU EIT EE ACA Mk BE TE I BK AAS Re AHR a aR EAT PASO) = BE eK IU Le — SBE Te Ti) BAS MiF 3A. BIX PEAS AIA ALAS BE IR INA TE De LR AY WULF T REA EBE LOEB EEA AL ALTPSENT TRL. ALBEE RAITT PAT WET AAG ATL AT AEG ZA RTE ME SAK) A DEAT AZ A HEMP AD ELE SRL OL Ge BG Ne HE 7 REIT Ab EE. PTE FP LTE AF BY I SUBIR TRACT SP A BG EES DBT HEI eR 5 AT BOGOR BTX 19 (ETO Li OE BE EGE A A UU TE RE OT I 259) LB IBGE ETAT TOR MAES TE. IAT UI A HEE A TAIT Ds AE DACA A WIC. A, ASSF HAMAR BERBE Fed PL fa 0 PA a a a PU BRI Se BE A AA EERE OR AE AAMC OFT? EARS OIE Aa He ENP AE A Ae A PARE FA HE AE SOU Bk 100U, #7 RI 2~ 3 AE, AL ane ae AE HAL FD Me Ok SC ULF ae Az A 5 RCH MT RAE 2~8°C ARE 4 IEA. AE HY TL SAA RIL a «VAN A I AS a FD LT CE Dd ER 2 a HE IE AT Ae TTA DEEG ah REICH BLA OE. JAG TA Te Bia BE Ff LER Ak EES A 0. 90NaCD VRE. BEALL. HESS RATA BL AD A RE CSL OB PR AS Hd 28 PT TG TAR HE —¢€2 AE Jun ai RB Smee a it (0. 9% NaCl ESTO (U/0. Im) 0. Sml 20. 0U 1.0ml 10. 0U, 2. 0ml 5.0U 4. 0ml 2.5U 8. 0ml 1. 25U i iy 66, CHE A, HRB AE KA ~ BC), ASEAN. AS2E ih URE A FTE ARE BEINE DFE BX PES ei EAE LABIA AG PEI 5 ELI PE A aA TELA BIT — . (Bam) SX i et RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol. 201036 1624-636. Epub 2010 Oct 12 J Jankovic. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiat (7) 2951-957 8. Cheng CM, Chen JS. Patel RP. Unlabled uses of botulinum toxins: a review. pa Health Syst Pharm, 2006;63(3) 225 4. Brin MF. Development of future indications for BOTOX. Toxicon. 2009; 54 (5); 668: 674. Epub 2009 Jan 28 5. Esquenazi A,Novak 1,Sheean G. ulinum toxin treatment in adults and children with neurological impairments~introduction. Eur J Neurol. 2010317 Suppl 2:1-8 6. Hallett M4 e R, Blitzer toxin. Toxicon. 2009354(5 20043 75 2.Am J ational consensus statement for the use of bot ;et al. Treatment of focal dystonias with botulinum neuro }28-633. Epub 2008 Dec 13 7. Albanese A,Barnes MP, Bhatia KP,et al. A systematic review on the diagnosis and treat ment of primary idiopathic) dystonia and dystonia plus syndromes: report of an EFNS, MDS-ES Task Force. Eur J Neurol. 2006 ;13(5) 433-444 8. TT ATA 5 WE HE «ETE. Fey ASA A100 A RE AS J A AL PRT eT “PRPEBEFAR. 1999.21 62~367 9. Jankovic J. Hallett M. The therapy with botulinum toxin. New York:mareel Dekker. 1994BT ABS ERAS MAREN SD iHRB BUX EAI T 19 FE WLI OE HG RWIS WIE AE, Mecige SEA iE OO AG A AD ESP 00 FS JY PA) OA I 08 I BT WL) AFSL GRACILARIA UL SEOUL BRAT L SADLY C1 (HEIL REIL BE FA LL) EL LAS Coe TAL RIL STL —. FR AL FRE HE WLCorbicularis oculi) + Ae A MFR EB be BLY HFS WA A A ‘RF 29 EF HG JZ IL A eT pA A PATE MBM: HMMA Y A KA, TODA ILE ML PATHE Se" ACT ETH HORA SL 5 GTP PA I BESS Ha A HLA ts UL Aa De rd LL 2 De IE DS BBP BD SD BESS AE 8 MP 1-1 PA 1-2 TAS AAT HS s A PE SP IB 2 A BT AML EAR ACT 39 De HE AB EE ST 5 Fie ia SEE Sh A BPE 5 TS J 8 ARF EP CP 2 A GR TE SF A Rs AR DS AK AVE 8 A a, MUL / si EEBM: 1. ESSE [BRR HS PB, DA Sede WS LR BCE WSR Se 2 FRE SEE TTF Ws AAMAS 5 BT FS AB AF LUD Bt | AE. 3. EL Dr We Sy ie PS EFL TI A, MIR BSI EA PAL ABC 3 LEA eC — 7 A RB ATL SP AE Ne PEE ASTD FESS 5 PA AOE I Wi BEB EE LU, ee —)All RRNA 12 ARMA REAR SARL ET fe 2 EW LLB HF SSIEWUCcorrugator muscle) «(3 FPA HR JE Hi (7 HE FE WL 2 FY ABT AE 2B 1k FA PY OE Be WK. PRM HC, VBE WIN ETS SOIT eT. TARLAC FHI Rw BOUT LEE e. SARA sae il SS I VL RD AE MPA 1-3 PAL 4 fas Pt 1. 25~5 PRE EMIT 8h eS TE LIF Vcr DAYS TES DA RTE RE CEE LL Lie Pa. Weel ia] LC musculus procerus) SE VLA AB BE WL RL AL SAAT BPA ED A A Ak SO A YP EGE Ani 8 i] 0 He PBR Be PS A FOAL. DBE HEI ALAM IA FAL GI BR EE HE PE RE Ly BRE PERTH 3H HS 5D WL AE MAL 1-3 PA 1d Spas s AA HEL. 25 iB13 SHAR aera 1-4 BALSA a TE A ERS: 1. TEATS Re Wee ZU A ABE, 2. HERES fev FY FRE RT JE, 7° A= Bi =. M38 ML #HAWLGygomaticus major) : 4 A HA. HEBEL ULAY Sb br. aE AAS HET ffs UL. 1 UL RE CULT PARE 1 A AI SC TARE: ETL fA Ib LT. TESS TTA : MALE Sb Ne 28 1 fe SP A UL HE ak EAR AS MRT 1-6 as 5 HA) fit: 1. 25~2.5 HL /R. FBRM: Le see Sch $e I th PS ES a HH ER TY 2. FY fe 2m IRS GES EO) BO Sh AEE Fi“) WLCzygomaticus minor) : ERR ACIVLAS OM FACIL i EL SUPE 9 Sb Be —@_AHLEBE ERE AL {A Ais SilArATee 6 BAM RUN ARES (0 LL SES ASE SEL LIE PAB A AB SB PBR Hh i AZ A Tae HEB I RE. A PTR ITY PERTTI : HZ Sb A Se ET fy EAR AL 1-63 HA AE 1.25 ~ 2.5 T/ Bie SERRE «i HF AAC WL Ae kW as BR AS Gd of A 7} PiKi. #2 LR AGB WL Cevator labii superioris alaeque nasi) ; dt AL AW BFE HY I FB Fe BSR 5 Pa PT ALP Sid RE 2 AP DB BR wa—MN 7 — 8 AMA MIERIE NTT ake PAS SE ALARA SMO SEH REL TE LH PRB: HT LA A I, SNARE = SM PA (ASD BE Sb A RTA ABD PhS SA JE. PTD RSE RAL AC RAR SS «CEE ERIE 0 CERI DG ERIE EBL TAY PRT ET Fa 1-7 Bitar 1-7 LRA RE A FER BIA: SERIA AT Pet. BHU Clateral pterygoid muscle) ; 2 44 4844 BG 3k Eek FAME a BE AL MET REAP igs F Shik FRE Ih TET. SAP AE Te Sb ak FF a KATA SHE PBA: NF Hi TERA EE FHL, eo, PERAK : (ATM A FEE eT Sb 7 2435 HS B27 10mm) 5 A fie Be A BETA Ay PEO VL AA, TD A 1-8. Fl 1-9) 0~60U)., FER BIA: HE PELL SG] PSE RITE. F PW Cmedial pterygoid muscle) ; HE AY PUWIEWLA 4 ALY PRD AR PY TT AUS FT HE FS RK A ESS AL FB A SP TF BLP MBSA th FMM LMA Y eA. MLE IGM LEY XZ He EPH» SC FEF OL a] FA A LA WS A fi THRE: LHe FRET BGT UE BE ULL CS OP HT ef ad Fi «LAMA LI 2a BESTA OATES «SE He eB PEI PE AF PS EY th BAT LIA Wea BD BE PLL AA: 5 ~40U,, 12B-R AMMBMIER: Dit SLM 1-8 RAM Re Tee 1-9 ARR AL A He ES A WeWLCmasseter) : 5} Jas + Bea HA 5 ke ARLAT Bae AUSF RB EBAY» RPP a OTT BO SPA EA. eek A Hi ob HS PY AN ANS ee SAF PRR EE PSC A. OP Pee AS DRA 1k Pb RK AB ANT PBS es hh FH LE aT AE PAWL Ae, SOD BE CE MELMEGIAS USEF BOR fe A PAL A FOR A A EBS AT TE EAL EB mT A Aa fh Be 5 Oe PE BA LTA RE. SP 2 TEST CAM 1-10, PA 1-11) s FE: 25~50 {ie / fl 13BN _*—# SGBBRERHAA B10 RABAT eS BA -1L RAR ARTE AS OR =.AAMA 11 ¥¢ ii WLCorbicular muscle of mouth) PSHE « ELLE SE 1 28 Best AS Te i] EY ULF AEE me 5 Ag A LB A AP EB PRBS AR : 1 SITE A A. THRE : HAV HF SLI a FES A PIR AE 2 eh CAL 1-12 (1 1-13); fits 1. 25~5 Mi ROS 00 fl ATL BLA SER: HA a Oe wT EY SI I. 48s AWM Sh BL ORAM Tee 1-13 CALAN REAR RHLCalbinus’ muscle) ; FORMAL + AL FHS ASR AT AAR BHAT Ef Sb AWE AT EO Fa AL IE PBA: i PAI AC. BE : 45 11 ffi Sb TRE AAR PERTTI SEI FARE SA SMM EZR PF JUL 4 S84 CPT 1-12 1-13) 5 fat 1. 25~5 AH. 3 BAGEE « SEIBP HY Ae BA X SakAN _*—# AHERN SERED <1) fi 2a Hr NL TT AB AP RE EH RT A EE 1 fAWLCdepressor anguli o1 FO AA PA = AE WA te AF BoE HE ZIRE IEF O fiat. PRB: ALE PA A THRE: 451 ffl F PERATE : OFA F Sb WERT. dee CAM 1-12, PAI 1-13) PEAT AAA 1. 25 5m LC mentalis) +7 2a Eh PLAY «EAE OE) AS «FB BE a 2 PWR RTE LAS. BRA: PLY Pa AC SVB FEA YS HP BE PB De AP HE BESTA: (A 1-12.04) 1-13), AAT RTA PAE 1. 25~5 HAL a. A A HCFWNLCoceipitofrontalis muscle) « Kr JE A CLE MUL 1 al AF OT AR A ELE. WUCLrontal muscle); fie F ATT MS RE FARRER FIT BBE PML Coccipital muscle) : {% FA Ib Mi). kz Ab HAR IM 2/3 ALB PLS A PA 5 1) Ay Le FAR RE TAR TREADS PIL JED 7 HH ESA AS 0 £0 BBC ek WU PA ob A § A AT RE PILI 182 Fk ea Sh ld ak SY CA 1-14, PA 1-15, AL 1-16) FAL: 2.5 ~ 5 of BE / Bio Bis BREST EA8-H AWMEMERENIR syn PA I-1S BRANES OR , » Al-6 MES CRT FERRI «ES IVs A A PT YH a JI at Je SRA IE AULA «ak FL ES 2 AG A «HE HT a Fait eae. HB UES HEPES A, i Te. & SUM ATE. WBE Pe SI HEY BL Lo fk I 5 eA EY CP 1-17 FAL 1-18) fH: Fal VLC platysmma) sy — Be VL » A Ei] «182 SO PG A AE a BAC LA SPA L Ae tT RAG HE Fo) bk AA PARR hi HA eH. ThA HL fat F I BAER BCP alte FAK by Be Sb Ze A Se Re «BE A EL TEST CPA 1-19 I 1-20) 5 Flt : JAMEL BEART AR 1/8 yENN #—# AMBER NZ Bi7 BieATee FH l-18 MARRIES A Aly FMRI Tee asHE AMBERERENA AE bt 120 RARE SERRA 25 9 TTL PP RR LT AS HES HEALS BML: FAAS 1/3 Sb 1/3 BENG 2~3mm BEBE EVA RE SE Sram, ok CS BAAN He HEL AF BE BEB CSE «AS. ete BEAN OL ae MAI Be Si PMR WEA IUUEE PA BA Be Pa. JES. BSP. Taf ee TD AL BT LAA OL (i FEC HAE. REP HESM IE ST RAW TES AI AT SK PAYEE AAR (2) ABE 1, 25~2.5U A A HY Be SAS FAL BC a La ES} 2~5 Kix. 1~! fe #109) 0) es Ft o A MUP AEE RTE +20He AMMEMERINT ype WIT MRED 3~6 A PALS A AE PH AR a GOS FE ST HMMA TT EM. CAL MF 4 3 FAY FA EY BA KR FOUL IF OE EA Tn] AAS BIST AEA 8D «BE i MLA SU WEL. BEAN BRL INL I Bf: — BOE BA VPA ae HE RES ATT AR z PEE AN A BREE OTE 1 JES FY 4S SEAR FPA ACA AS BE ISLE EL HE Re AS LAY AS BEI NE AF APRS UL WB ae Be RP ASHE UG REE LAS BIO BEB KB BET BEREAN | Fb Sk CON MBE BSE HED iE SE R sf FE P88 AS in) LT A PR WB “D> SE TZ Ff RET SIG AS BETES BZ. 2) Be HB = BE PP I IL 9 Ed APE A SF RE LRYOAS ED SPAR AMAR EY Be Se PE PEE Le IL TET ELE} Oe Wd iat 0S BEL UL DA GRE 9 25 SCR SF 95 bE TA DT 2cm Xb, BARA AS A = BRA» BAG TF PA Ae SM AS JRE Hy ORT HAD SEA) TMA AK 1) IAD ASRS AAU SS BAL S> SAL OY HE FR He A NG HET AE LE B28 AR TSCHE FAS HUL Ia] BaF DSL» HEIR ERY HR 15° ~ 30° DEE EG NTE AS BP i AE EL AS BE OT 3. MURR PAARL LA HE 54, UHR AS FY EAT 4 APR PRD 1 SE Ae A AR PRR RS HE MEM i BG Ae «AR TAIN A,» FS OR PETA] 2p GS PRE AER PD TE AS Sef ARE RIS TEAK DT ABE « PED PSTN PA WD (AE I PE RE NIE ESD ICSE AS Fe Hl MRT RAE AR LSE AS. PRACT UL RM EE AL > I Ti BABB ILAT. WRT IRIS. TFTA : Botox® EIN AIT 250 Mi FREE WN SOU/ml RW BE AEST SUT POG Aas » PA PFT] ARR BO A LA STS 3 KALI 2 IA ATTA SB WE TT HE 34 qi is z bi} au. Bhidayasi SATU « BREA HAS A EA a a HI RE LP 9 = FEWER 77 iE, UR IIE TE BAT VEN. TR BL Ca Ha . Hallett M, Evinger C, Jankovic J, et al. Update on blepharospasm: report from the BEBRF BR RR EH FEMS Ty RIC (@=2. 5UX 10=25U;4=2UX 361 SA at if=31U) (KAR BRE) BALK ABBE ARLES} Se Se RI Bes EAE. ULSI HBR OG ae. A #EPL Bea 2008418) R lar dystonia; comparing different botulinum toxin preparations. Eur J Neurol.2006,13 Suppl 1,21-29 70-573 doso F, Truong D D. Botulinum toxin in blepharospasm and oromandibu A) SESE. 2 PHBE, 2000 ,26(2) : 104-105 305 9,963 International Workshop. Neurology. 2008,71(16) : 1275-1282 \. Jinnah HA, Hallett M. In the wink of an eye:nature and nurture in blepharospasm. Neurology. 2011,77(7) 616-617 . Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm, 2008, 115(4) :585-591 ‘akmur R, Ozturk V, al. Comparison of preseptal and pretarsal injections ofBH AMBEMIERENT yee botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002. 249(1) :64-68 9. Cosi 1. Botulinum toxin type A therapy for blepharo’ )05(1) :D1900. pirito-Santo C, Borges Aye ochrane Database Syst Rev =.nhe!e# 1. AREAS A TET PS Ae Ly — fT PALA A AS SH PA eT) AGAMA « CEE PE BaF A HEL A EI. 5 S28 A Bk Vl YT I HAS PE AT A SOLAN UL 5 > SCAB AT Jee LS Fs) At 5 ARE LSS SBCA EPS my. SALA SRP eT ACRE CAS SLB 2 ZAR 2 kB ‘RE NG CF EL OT 2G | ak tL 20 TPE Se I SERIE. WL ARE PG SATE IE HE 145/10" 5 Ey 7. 4/10" 5 A F 20~80 4 FEW BEI 5 PLM Ae HL» 1/1000 Ay ARAMA » LCE CE XS Be AE AS ARTE. HJ SD-TOF-MRI fe BSED I YAR AE HAS Ag OE a8 TTP EAR PAT WE IE EOL s 3D Ea AS UE oi A AF constructive interference in a steady state CIS) ii icf S038 Hi FF HO Fs fra 9 FF SEAS BSG A as TE RS OT PL FE ELAR PO HMI AB OG FA 5 HERE AR CTL SOA. T 2 ITAL AY HE RE GE HELA BRE FT Az BL AE PL ac AS UL ARE TA iS Se SL 5# 96 LIZ NZ (abnormal muscle response, AMR) Bll HEL IEE AU AT BES HES FBR LS Wad SZ Se ME DX UL Pt SLA IZ I,» FX — GAG HU PG I AH OE FSS Re e InE T B AE nie AEB (synkinetic responses, SR), HN) FUE LH 0) 1 I RA A A a 8 TAI LAR OARS 25 CR PE TS a PE WUE A BPE WLALA A HERE RTE AIT UAE BE hadi —F IA 4 UN AEE HEP A TAT IL AY VA fy A ERE AIT EZ —.76%~ 100% RAE ESI Sea He AR WY SB ON ee A ST ASE TB] 3~6 A FALE SLE AT TOTAL IT A. 2. PARMA TEATS AS DA An OT ILS He HS IL Be ECE AS AE ED PA HEIR ILA ae BE PN ASTD EA AI Da PAS AT 6 CE AA AS ESS PE TF HS AB ETS PB SAS A AS EA He i a 7 i ANE ASSESSORS 5 TF] (UHR I SB IE Ja SST LA 2 20 VN A 8 SH a A IL HEAP Le SM a, « SSD WO SP 8 BT YL IL AIL IL CR IL, WL BAAR Ah EH 4 RP 4 SS TT PAS UL i Pd 2 99 sf EE JaAWUC2. S~SU) Jeg EEO a AS BT PA AS «Oh BE ANB YA ZA 2 spasm{ J).GN #— = ABB MIER ENA SY OTT = DAE PLS FR EIT Lem SF BF Bt KP IE SUE EL ft BFL FE Ta) Hi HAD 2 WR EEE TRIE SE HEBER OGU) «7 5D ail Hie “4 a > FA fat UE SH FAL tat Ded eal? SAGAS: BG 1 Ae ew Ee BRAG HE AP ABE PL DE HA «os BEET FAD A Wa Ha a St ABs LA ae > TALEBAN AF BE Ae AR BLUME BIG HA ERAS Lg IR A TRE SAD BASRA TT BBS AS Ob Bes AP SG AY AS BR IZ in, 5 PUP I BB SE Be He 8 3% ~ 10% ) HRB SL HS BD ee Ae NLS BAEAIR s AS B52 Fk — ABIES Oy BRE ~ 2 J SP. RE LAS IZED TAA CD ENKI PEA Et I Cn 30G PASAT Tea FE OH HE HS AE HN ASD a) FSR eas ES: I) ARB TE FO a DBE Ae uh EAE 28 A EA PAA Ta], (2) BLAS Hb BAAN EF = BA J Va] IL BE LI PA TEA TH SMI A AAT TE Ss a REE AT OM APPR EH (3) Elie Fae FS TRAE TA BE GU We PPS DS SSE NE HE SAD SAE LL De Voorn DAVY SE PLES HR ES SU A Ed TEL 5 A FD fe ESAT HAE CAI AD We oR SR Pe SE sd AE UL TR De ee HERE. A) SLD ALB HAE EULESS E PAB BSB BD i ee Es SRE EF (i PY A Ak > A a DA Se a PCA AIL] Bi. 5) 0 $6 FE AUFAA 25 AS Bs 1 REIL A GUPTA a J AS FAIL PBE WL FAL EE s Leb? LA ALIN 182 5 AT BF HE AS RP FE 5. SAY IG Ps, HKU. 56 YATRA A EBAY 2 AE NRG CR SOP 0. 1g, MEA 3 5 FIR FER AAS SL OU HBL TIES 3-1 $F AS EAHA. Scout FP IV BE, TERT RMF : Botox 100U, MURRMEE 25U/ml, ARATE NT 98 ME 1-22 9 Fa TRE FAR IE HOR 5 A A DHE AC Le Le TEST. VEIT OS 3 FOR, 2 TS Phe TP RCAEE dS CAS BLL @|. Odderson IR. Botulinum Toxin Injection Guide. 4 #k U1. 2. At 4 BH AMBERTERIND sya 122 MBF BHEHARIAR SUs a= 1. 25UX2=2. 5Us HEAL LET = 27. 5U) (@=2. 5UX 10: (We MAR) SUK . Fruch BR, Nelson CC, Kapustiak JF,et al. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. American Journal of Ophthalmology, 1988. 106; 45-47, AUR EWTN. AEE eT Pi Ite WER OLS TAS. TARE TAILS. ABR TA: HH RHEHE «2005 « 126 HAP BLE TEAR IH REL 2011 de ak OE BEG S. GRAY'S Anatomy. The Anatomical Basis of Clinical Pract Ab APPR FH ME » 2008 RAPA. de 6. SEAR SC. Jer AERA. AE its AB TE HH RBG 2001 "PAR DRE Se EIR S} S e EI BG oh RE EL, AULS Bi OS HO GTI HE #6 AAR 2008. 41(8) 570-573 Simpson DM, Blitzer A, Brashear Cy et al. Asse ment; Botulinum for the treatment of movement disorders(an evidence-based review) ; Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2008.70: 1699-1706 . Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial m. Journal of Neural Transmission. 2008, 11MN _4— FA WMEMER TR =, Meige 84 1. BEB Meige Si 47 FE FMM 1B SIULIK J BCE «J T° 15 Be A UL GK 7 Bl EE FY FR SCHR UIE) PAUL AVL Ae BE IR 928 SAS AY SIR TAL IEF WR NAT. He OE Ee ME a A SF aE ADEE DYFED BFE BAN LE A BU) Spe 2 PS ke CT ILS JAA AR A HE MRE TK GB AE BER AM AS AS PUL HEL PRL 4 Be 98 SHILA. Gk SY VLG SUB RE PEIS ON BD I PE AN TE FI EH US RE Ae OE A EAS TE AFF TERRELL AS PE EP RPT PRA TR EAE DIA PRL TLE 5 FH ESI BGT fa BE EB P TAIT LS I Bi HEA o> Scio AT PE HR Be 5 HEP RAR AC I LOIPR PAS. AEA RE TEA A ATOR Me AR AY PR AT Fr tds ABLE PF ROUULIK J BA 2 Ee RE PE WLSKG J BREE Pie FPR PE ATA 2. PARE TEE AS TESTER ME. ABI AL BEF be. DA HOLES ARE MR REAR BB AB, DALY Kv] SCHL IEEE BATE SRI. APPAR IS SY AS) ACHES A A EAB AP BAT ae PF OUULSK 0 BRAS. OL FAT 5 PF PA WS LAE ST EF GAG A AB Sb LE SO SE TR PASI 2 AE TSWV PS | ° BUA WLAL 2s 0 WE ALE Fait A mF rit ELF FO UEEL ALA FAFA 0. 5~1em, PO AS fe LH Lb ZF BUSSE HLT. HLS BALA Fe ATS BEI ft SS AY FE FR WLS HE RETE S FAUHE WL 4e 1-1, REAL GRRL AT HE RAL HEA A ES HE He CATE A FA ME TBC) AiR Ae a PER ALA BRE art wl 1000~3000 se 1000~3000 BAHL 1000~3000 Fem HOP 40(20~100) 1000~3000 A EAU 10010~20) 250~750 Femi th SHAE 40(20~ 100) 1000~3000 SAL 15) 5 1000~3000DRE LIERESTS AD BER HEPTANE CU) Wi RAE, YE FR BRL oo pres “Fev POE AL 15(15~50) 1000~3000 ANGIE 40(20~100) ROG Fem AL 15~20 uc BE WL as 10~30 500~1000 3. ASBLICINL ET UUIUUGK: 7a EAP PAE SET ERE TALI BAS I WS BE FUTEST RE LA AY HCD AK» 8 BAY SEE 4 AS IL BAS BZ 1h TR PEN PE A PE REISE ELE Hh 6s EA oS WERT. AO EE. ete 1S Fe Aa BAG 5 2 JAC AG GAS A SLI APM BS AR A Gk DPA GE dF A SLE. EP LUE STI FE HSA PRE 6 SH PEA Fe ALA Pe F AY i ALAA TAD SE TF OUGFE POY A A EET HAG RB OF LTE | PIT AS EAE PR LURE ATA TTESS BSE IMAP ULE St 0 RA ALT FE A SIP ULE dG AT, A. HEL AS ARE JRA ATE, 38 YEA AMR He AS A EPA PEAS A EEF 5 AOR BE REET MEDIAL UE 2 RC OIE EE. RT DONA SPIRALS. BEHL Omg, AEA 3 UWP RAE. Shi MRI ERE FTI. TERITR : Botox HE 150U. 100U/3ml., TESTA Lie PORE MEL SOU , SLM BE AL 30U/ fi «LH EL 200/ tl. TESA 1 JADBL Ie. CH A AN BS BI EES 4 A (RBA) SX Tsui J, Calne DB, eds. Handbook of Dystonia, 1 |. Cardoso F, Jankovic J. Blepharospasm. Marcel Dekker, New York, NY, 1995 \s T,Shanmon KM, et al. Tongue protrusion dystonia; treatment with bot- 25, ulinum toxin, 1 . Bhidayasiri R,Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia; different botulinum toxin preparations. Eur J Neurol. 2006 ;21-29 - MDVU. MD Virtual University. Adult Dosing Guidelin Botulinum Type A(Botox). Edition 2. 0. Revised August 2005 Management of Dystonia with a5. MDVU. MD Virtu:l University. BTX-B Adult Dosing Guidelines Edition 1. 0, Botulinum Type B(Myobloc). At hup: //www. mdvu. org/library/dosingtables/btxb_adg. html. Upda- ted 1. 28. 05. Accessed 11. 30. 06 A 1. BEE MEE: A SAAR HESE 38 TA A RE 15 RL: FE ay FERIA. FT oP DR ee Ag FB WLS REN AE FD SAT td SK TH AOE TKS. ERE: Ti] BAPE 4 NE AL i EH tb POPE ATR YLANG 25 i EAE FHS HLA OU SIG TSA AEE SAL Gs A ASE DATE « Aa ARP i Sh FG PE IK FO SL RS AE DA Se SSG eh KHATER ESA AG EAT 2 BE FL PTET EP PP TE A SUNT) Di 2 HE PRS. HEE: A RUE 1% 2. PRP REL SLAG STE nb FR TERI 5 — AREAS BE td SH THE AQ AS LAE Wl HH ITF eA AR AT OE Pg EE WUE WEN AS LR et Ae PIG Be SRE RE ORE OR ZS I tb SAG PT LL. FM 1 DA BE A AT BP TD I PARR. SC BE PIR Ai NG PAP Uh aE ATE HD SHE LE 28. YR J De a E25 TAIT IAL EE th ETI HE , 25 OBE L2G 5 SATB SE BEL aA dn TEBE AN SEF E RA AR 4 25 SF BELT FAL 0 SAU EE A CCA 2 BT OR AR 285 ANP UREN FEMI BAS FATE ETAT BS BE TEE PEAR HF VA 25 1) BALLS POPETATT «UNE Se IE IE OSIM AE DIB SVT ATIF. WBE LE BETAIT 2. ARIABEER AIT 74 OMIEBE HL SLAG 18 hd Sh SAT 2B. ARIE BLES II William Binder WSR ZTE AT A HP AEE RE 1 TE EE THA AL EO EAR SE LAE VA] SHEE Fea — AR NFP FE ROTA A EE ER REIT Uh SIRI AT IRC RLF 1) CAI AOL EMH A Ha ARYA IR PAL REE TT a DO HEARERS 182 HE Od SIG EY SKI Be EIR DB HE 2 A ED BDA 2 HA FAI BAS A» BNA AS BE TEE Sh STE Wid SHAG ALE 5 BRS — SM Be A HE AE FL SL A A BUA AR J a AY JH ZG HAE. 3. TEST AB A GAEL ARE PE LOM ERS HA BOCAS PENHic 8 MAL 1-23 JURA ETS SU, Ff RAR PSR BA (7 ei YL GS He PE HG DK Ja CPR] 1-24) HY JM 1~2 Minsk TER SU. SALE BR LE 200U, Ae ARB ILIN BBE -A PS RAE RE AIT EEL AE IAS BI INE ACB AS HE —@ ESE 224] A HUA AE RET TAIT TEESS AMMEMTERENT sya 1-23 EEA LA BE MAR LGU) 1-24 HEA SOLENT 2GU/FAL SBA, CAA AE AT HSA ASH FG J «HY LR Be SULA 2S ATA IRR. Hy BiG AL SH BPE IG ANA 5 (09 AS BN «FT WW > PS AS STP A PE A BRE STAM. BATA UR Se Fae ABE STi es BE TS (ER) ee a 1. Wang SJ,Fuh JL,Lu SR, et al. Chronic daily headache in Chinese elderly; prevalence. risk factors,and biannual follow up. Neurology 2000;54 314-319 2. Diener HC, Dodick DW, Goadsby PJ, et al. Chronic mi nent. Nat Rev Neurol. 2012 Feb 14;8(3) 2162-171 3. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of 1e~ classification, chi and trea migraine and tension headaches in adults; a meta-analysis. JAMA. 2012 Apr 25330716): 1736-1745 4, Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine; results from the double-blind, randomized, placebo-controlled phase of the preempt 1 trial. Cephalalgia. 2010330(7) :793-803 5. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine; results from the double-blind, randomized, placebo-controlled phase of the preempt 2 trial. Cephalalgia. 2010530(7) 804-814 6. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache; a randomized, double-blind, placebo-con- trolled trial. Headache. 2005 :45(4) :293- 7. Dodick DW, Turkel CC, Degryse RE, et al OnabotulinumtoxinA for treatment of chronic 7 migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the preempt clinical program. Headache. 2010 ;50(6) :92-136BT MAPS LMAB WIM IEMA 1. SHPAWLCplatysma) — PSA ER A BEEP Be A =F JUL A AC US SF) IEF FAT FRR FA. HARE = 11 94D 5 Sf LE Be ACH SLD MBAR: 1h PAM LA. SESS AT I : WPA 1-19.PA 1-20 Pr as » HAD TV Jad 8 Be WR BWIA ea Ae TE Sit; BAP AMMHL 2. 5~SU/s8.25~100U, TERRIA: 16 Bah bk = ffi SRE SE FT ERC 2-1). Siz Wk = fA (carotid triangle) {iF AO AFL IE WL LAST R TL AN LD BSL AD HL AVL Ys ALi]. SS IK DI SZ SOL SEB eB XK GEMA RID KAMA BT LEG B21 AkerGAN _ £58 BSELERE NT 2. HMBLFLIEWL(sternocleidomastoid) — {iF SAN AM BEF AC BB Ay SAL JOLT RL. EY TABI 9 SS» 9 eA HAV BY FLIER LRSM MBM: hee Vie, APA = FA sca A AF EF 5 A Ae id Fs A YE HES JA BERTI : ATA Je HZ WULIAL a P 2~5 TET CR 2-2) BPA AE 10~25U/s.25~100U. PERRET HEE aK PAK. OL SNE S |BP AN B U = 2-2 HORA SE ALTE RTE LAT 3. MAW Crapezius) LPB ANY LPB A ER De AY $F dL A HER Sb RE STL AF SS 7 SOLA AN AE A RS 5 PB AY LS aE TA Ob Te + PRB ASE AT Th PRB AY a Tb es EP SM 1/3 2} we A AAPL. MBA: rh Mes Mie, SBE (0 UP ed PEED «ALR TEBE AYP BUS TRB 5 SR a HE Ds « — A PSH a EE ey Fn SAP A «a Hh SANT aM. TERTTIE: 5} 3~5 TEIN CA 2-3); BA AE: 10~25U/ A .25~100U,, SERB: ESTE TAIN TT ETE AEB 7 9 TL. 4. JeWLCsplenius) ike A SIDA RABE 7 SUH ABR 9 AL AN HE « WILE AE Be) Eb ik FM EPL ASL ~ 3 BEBE FE. A} DAB : KIEL C splenius. —@(Sze FWETRAND yam B23 HAMitM eK capitis) #139 WL Csplenius cervicis) , 3k Ae WUE HO BAL FS WL Le Sit VA» A FFL FS FB AL HER AY SMO AB 5 BIKE ILE Sk SE LE SP ALB 7 ae EA MBM: hh 2~5 MHL a KAISHA. DAB : Al) Se AIL Hee A HD 5 AA 2 FE AD. PERI: b 3~5 MTEL 2-4); BANE: 10~25U/ 44 .50~100U.. TERRE HF I LES AG ATTY BRB FE Do ES YB Oy EBERT. 5. JABPHEWLCevator scapulae) (iF 20 RPT AAT LATE AL AL 4 3 HEA BESS FA PS EA. MBSR: HAM Me SARE s LEAT IPED « 3 (0 JED NIE TS a Se vd 5 AD sak «TaD i a Fi il Jatt . BESSA ATI STE Ce LL SPE CP 2-5) BG AEE: 2»—24 LRA RRA EAE ‘1 ~100U. ERB: UEP LRAT TT ETE ATE EARL. 6. #AWL(scalenus) #5) = BR EEE PA TP a 8 WL ike A AERIS. TARBALL PF HT PRA WLE FSS 1D RWI Po 2 A. MBS MM AC, DAD Be: — Ack» ESN 5 SO CA AY DBE 12 ROR TESS ATR «FT Js iB 2 RG WIA a ET CRI 2-6) 5 9H HALAL: 5 ~ 10U/ SER «ih 1H LAG SL Hy Pid Hy eh FL id ak» EA ly ae BA BAS ALS BE LE 7. “EAL Csemispinalis) 43° RULE IL A UL 5 HTD ZEYERVSHDS. SF MUL Csemispinaliscapitis) fit F IE WLZ Fi AL OH BE FE AP SHEET FS» WLP AE LF 56 EAT A EP Le PRT A Ta. BE HUVLCsemispinaliscervicis ) 2 Fl 1 HOHE AY BES . fel_L- BALE SITE BESS BeSIM BREMEN AY lgB 2-6 MME EMABN % = MABEMIERENAR PASM: Hh HFS eA, DAD = fie a Hv « A HMAE: SEA 27:59 Rite EBB OAH if SL AM ~25U/s%,25~100U. Bet VLA» Ja SUAS WILE 2-7 SREY ELI 8. 4K WlCmusculus longissimus capitis) #2 AF SHE EOE BE Wi Le PABA SL IS ZEAE ULES Mi PBR: 1 MAH AC. SHOE : OL NMC 2 HS SSP ERK: SSK 2 95 Fil tit . 10~20U/# FERMI: HFE 9. 332 NLCchomboideus muscle) ib& F545 6,7 LEFF A AR MBSA: ANT HS ZAC. DBE 455 EL SMES Ta PO ARE SE TESTI TE EA AO I A ee Ld SB EC 2-9) AS FARE: 10~25U, 50U, ERB RUE TR Hb AA LM, SMARAALA FASB RIERA IK «LUE Be 4 Be, SP Sl Ay SULFATE UL 28 SL a WL. artes (sae «yb LEM AE BE TE ET es HEE EAT A, SiS WLP «Nai 37% SUE ANS 1~4 HEY RIS eeSie BMEMERIIAR fee JES PAMAISL, GAL TED REINS «FA AF LSC PA SLE HE PE fay Fitigk oO. AE. 28 SCALE MELT dino B29 RUAN EAR SDL HEF BEERS Be A eR AP CL «PE A PLE VAG «SHH Es PS AILS AA 5 iD FG I 1 WERT OH. FE A WL J LW LES ZT Feo AE WL (86 FAIL BO = FTE SAU FO ALLAN FE PZ CE ALF Oa Fa LTR «A AF BC RR IE FePY LLY A BE ES Ae WL SL EM ~ 2 LOU, ALL 2 SPM Lm ZAG Hy RESIS ak» PSA Sa eA HATE. 2. ERAS ULEAD APP BR PAS Let] XA UL A ALAA kPa aoa A210 FALMaRATEA JUL PURE ULAEL aR CE 2-11) SAREE ALS EZ SP SS AY PECL. PRR ILI PS IULIRE — FARE Sb AL 5 PAA LD I TE IL PF AM B21 RAMRATSA=¥ RPERERIENTA LYE SRAM Vb Ii + AP RART URE ARETE PRCT AY emi FE FTP. Ra LATE SOT AEA E AE AR 2 OTL AR J FRED: AGREES ARC Tei ek AAPA FSET Dee «ts a PH A DEVEL, FLATT Ae ERE ALT 1 EAT IE IPP AS AS ELAS «IER HDT PG SA DAF FUTURE ARIEL AF LT Pe AS TIDE 2 aS BRS PPAR AKT PAE APPS MCAT ES | ARACEAE A TPR. EET HA ABA DAK (DERDA A « BOTS CO ARE. ULE PEL S| SR 28 SU Me A FE TE Or Bea A PIL SETAE BEDERE FO BCHETE A SP PAASSRINSMERAL APIA UPA ae EE AI LY TUL ABS FS AE GS PE AS AINE ALESSI AAR IDI LEIA MS BITE AT ALR LIE ISS —. BEAR 1. BGR 228 HER}SI (spasmodic torticollis, ST) Jeli AEE BA AY WL 7 Bie AEA TIER. FEE PER SINT 27k PAE SES. — RE IE tk THE. KE te MAGN e AF iy BOT WLR AA LAY ia Hy As SL BO) RT 2 Ay id WT HE Sk SE I + FEY”, MEAS SEAT Te] — SL AULA ATE AS ELIDA Se FE SHS OT VA SEAS TAD LS 5 PS CLAS TAL PE ECHR AL 29 ER, RG al UL eS Se 8 0 2 LU A A BE PZ ABIL EG RAS BARB WLAL PEI «30.6 Hk Fa SIRE Ha HH AUTH HGS th ES HS 09 A I 45 SLE HS SHS HY BAL Sk MBE BM (dystonic tremor). 4 fi 1/3. REL A EER. 49 10%~15 AUR OS 1 AEP AT AT ESA PERO OR KR SLB. 21/3 A Be EA STR AT PEA A HE RR BOW a BEE WLS YB HF VAL IBCIULEK Ig BAS ABS EAE BRP UL HB LB ER Jey 1 FR « (ELC SOY LTA 222 SCV TA iBT SAAB LSI SEA AY RVR ARISE PE RT AGERE PH A HE TBS o—BO_ BLS A SIN BPP RITE HH ESS SEPT SS 8 NCTE STAI SIT SERIAL SURRY Fe ESOL AB ASH EAE EWE RI EI PE LS Bar BB ES A BREA A RAI ST Ig PSPS J A 2 DE EE EH 2. PREETI 9 FEE RSIS RICA EAE AIT DIRE GZ RNA BEA SE HDS Fay ELSA ARS EAE Tk 8 Ae EC 2) Jed PEIT + 3) nm AAA A) SHEA 5) Fl fe dia HE BR IL HEA HLTA PE AEE EAB BU mB A 1) Sk fH SAAB AT A Pa Ae BP IT CE 2-1, 28 2-2) 5 2) SHURE: (HAR CSA AE 3) SOUWLPE A MAE HE ABLE 5 4) LEB PAS | EBA. R21 HALMGAR BHE EMM BIER SBE CEA 11 4H «5 RL IL) i 1 HE «1 3 ANS SK ILE POHL A] SOL OD 5 AE RA A Dl WANE i Jr FAL «Fen he SOIL ag 0 SAL «Fi STRAHL SecA» Fl HL 4 3 Fl R22 FELARLERAKARAVMA i AE, AY fie Be PEED 9 LP Sk Bin LU BEL Je ALS LAE A AL SLL SR AL SUTIN | ALAM SKIL SPELT WIL RL AS ELL UB PL EAL AULA She SAG AL BE AL RE AL SAP AL Sk BUC DL kb FAL AL He BO Penie (el AA, LK Lk EPL Sk FLL 3k CASE Wh | AL a Aa EFL LSABt SALE (3) 6 LSI RMU 9 BST A: UL 28 2-3. R23 PRAGRAMAVS SEHR ALPS HPELA PP UC TEN FA BEA IHU) Botox® Dysport® NeuroBloc® wate aL eM 10~100 s0~200———-1000~2500 SEM 60~100 200~400 2500~5000 OTA 25~100 80~200 1000~2500 JARRE AL 25~60 40~100 500~1250 RAL 15~50 40~80 500~ 1000 BRB ADL 30~90 60~120 750~ 1500 hat FL 10~30 40~60 500~750 Be MARIE BAS ELI TAS DARL AD EY 8} S08 8S BSD AST] LT) SE POUCA NRE. Ze RCH WL EI Celectromyography « EMG) (iy 5 36 tii 3 SUC PED LU ti A Ae MBE 1 SE AS EB a St PPT HE DAL BS a / AL, DAI IRAE PE RIERA EA RA F215. 6 FR BRET OHS BD ASE FRY 1/2 LEED TAAL AM / ETE SAE PAA AT IR RP PR A ‘BE EMG tes 2 DAB I HE SMT SE SS RE AE A TE IS AS HL PAGE AS 24 PAS PAB SOUL A SHR EL TEM ak AS Ea HE UL DE STR AST BEATE a ig ARF NES, BOLTS FE WE AE SL — Bt AS PE Bg PLS VAS Fa EWC | St 1 SL 5 FRY BRL LE TAL BE “1 1S ZF EBS ECHL SH HA (EL BPI BY Bs FF ILI BLE. FON SHAT HT AMT SK EL A DR 79-3 a CIE tH ALS SUSE TL. PEE JDL VAG TE TE TAIT ORAS HE. WES AEP SE LZ LA Se BCE AT FAS SE 928 Ee SIT A PSLRA i ABD DDE TA EE VN ATT RETA. PERE BY SSLTE SIT I (09 HE UL AS BZ 1 LG TP RIA UL PI WUE AY GG ASE PEN ASAE TP ASB Ba HAR GATE I BEAR BR BRINE — AR PRISER BE TE TESOL A EY FE ERE HH TRS] A DY J BRE AB ULF AL MHE » 2474 20.26 ~ 30% « AG ey FF MA AS 3 NE ae D> GE 4)—MANN _ 253 SEI eI URL ME = ED Ag BX A. ih sek PO SB A Sb id A A Fd LS WEAF. AG BTX-A. AHA BR AR UL AS AR AE BVA RE AIK VENA BIG ANH EWR AD HN PL FUL UY TS HA AE 5 DI IE Se, te FALE. 4. PUD LAL 57 8 CPR 2-12) AA ES Me HE 3 4 AE HAY I BS SS Eft BE yg © AES: AS ES AY AHS» PES 1 As BT BR A AH AL AO RL UL A HBA i BA BL PY 14 SAE 3+ AUB 2+ Fer 1) >< HRB 2+ TH 2+ Sh NC if 0). ATE TE RTE SATE IT RK : Botox AFI Hit 250U, MVAEMEIE 25U/ml, Arti kK WL 75U 4p 4 20U, 1SU) FEAT » 47 fil Hd BAFL FE WL 75U SF 4 xR (20U, 20U,20U,1 2 EIT WL SOU 3} 3 88 (20U, 20U, LOU) FE At. AF (0 A HEWL SOU 4} 3 2(20U,20U, LOUD TE: A212 SPEARS AT HAR PAB TE AE ESAT at — JELLY Sp 2 SPL A 1+ ATE eA) 1D > Tad 1+ JAAR 0+ eu RP APPEAR 7~8 SP. TEAS BLL BEE “FY SABIE SEI ANH (BaF) BALK 1. Kessler K a M. Benecke R. Long-term treatment of cervical tonia with botulinum toxin fety,and antibody frequency. J Neurol 1999, 2, Molho E,Jankovie J, Lew Role of botulinum toxin in the treatment of cervical dysto nia. Neurol Clin, 2008 May326 Suppl 143-53 2743, Ferreira JJ. Costa J, Coelho M, et al. The management of cervical dystonia. Expert Opin Pharmacother. 2007 Feb;8(2) ;129-140 . Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006 Aprs9(2-3) : 145-148, . Brashear A. The safety and tolerability of botulinum toxins for the treatment of cervical dys Expert Opin Drug Saf. 2005 Mars4(2):241-249, Swope D, Barbano K toxin treatment of cervical dystonia. Neurol Clin, 2008 May:26 Suppl 1,54-65 tment recommendations and practical applications of botulinum . Benecke R, Dressler D. Botulinum toxin treatment of axial and cervical dystonia. Disabil Rehabil. 2007 Dec 15;29(23) 1769-1777 . Jankovic J, Hallett M. The therapy with botulinum toxin, New York; marcel Dekker, 1994. =. WREBAULSK 71 RAS Le AREAS Jr RRA SR BR AS AULAPE (1 UL GK As BCA sg SUL KG J CAR. AL IMLS Ay BA SL Sy 2 a TES 5 RES A BR 5 > LO HE IUGR 0 VATESCHREK UIE SS LAT 30 BY RW RELL (63%). 8/10 Jak F PWD PEEVE TT ETT PEAT FT LAS ea SG ALE SBR TIE EVE PPE Pe FF ASE FUE PE YP RAD REA OU | PT] AST SBD OY ATE Be AI WBE AY Be PT. PRISE WE Ey Is IS OT «ARC A a SEALE Se ad HAE WALLER Ae CLG 5 HANEY Ha OF PCL «CM TS ZG WERE. RET ERAT AR BE. TRAP EA ELF WSCA AED EE BRAS AERA» FF LEAS LIU STB AS — FFE aL BE A A Pe iT A PEDERI OEE EIT TEP EEEE RAITT ZA EEE RT TT REN TAIT BOR SAAN. TT SEE RAAT T AS AL A — ie BE BY LB — I EE ABS 2 PT AE CI HS 285 PAA IS LG IRE BEEF FETT EE BL — AU RHE AE BY BS WTS EE KB ARR RC LAE HH LP EEA EE «LAAT TTS A A RE RS BEET AIT ARATE HLS VTL A289. A. Blitzer F 1984 4 4 FUCEA TT OCA A 2d PAD aE RETEST UL FR LIULS Fy BRA TESA TEAK BS. AH A HY EEE BE TET RIL PE Ee AT. BLE SE FRA ROR — SL SHP BLE STAY A HEY PA BE RE RE DE TAIT A BA 9 FF. Blitzer, Brin SEC e eee Ane HL 1100 fi), RHE RE: Bre eee ae ve fig .0% RATER EAE « DIN 2 He ae aU A eR a @MAN _2 52 BAER ESTA 52% BCH BI 90% FETTER SER Ta] 15 Ji WI ASO) BR Na ALL. DEED AEA LIA 16.6 BC HB 84%. FRE A HLF BE 55. BERG BU 67%) FT MAPS TAL HEI 10. 5 JAD. 2. LURE ATED RSS AAT A UATE TE RESTA TT RE EBA RE LES NY UR OT AGEE ABRIL PM AEDS Pe A HR FL A FOWL A UP EERE TEST. SRE REE I A BEE PY J LE. SL MEF Be GE Oy RA A A EER OM PPE RY ARAB TUTTI iC I A FALL ETT EAA PAR AM TAIT EIT AAPA GFF BMT” LE ASR EB Wf ELE RA AKC 2-4) R24 ADARSRAT SEAT HB SZ Be tL FRM 2 BK ai] AULA UMM REST CU) VACHE BRL OL 7.5~10 Se OH SRE VETHIL - TEATTITIA AT RA BEF RN BES EF I LH | ET De he A BEER TE NAR 5 WL RE AAS SE PA BE» Ft — 29.9 LU Botox, ix Jet ‘hs BE HDS ANF SY Pa a PR TR ATA ad TI TI Soe A AL IT I FEILER AS HEAD » BEAT AT Pe SL YE Je 93 IMD A at Rb FE EAS AA IC HR POE a HU PIWLEEST 0. 625~2. 5U Botox, MF BRE ME AT L128 ARF 3 4 RE. Sh I POPE BEML A) kee EY 3. 75U Botox F-— fi RPI WL. 2 Wi Ser i ak A BE aE BAT A FH es DH A AP A Et Le HUE WE ATE 9 4 AS BY) 5 HEU EL ARE Le Ok HE BL AS A FA ik yw UA ie BE SETA ATE 5 STR FL FADE BRC AE LS Ht AS 34 2) JL I id AS J BP. SMD EIT PA MBC HD FSF Be ise RL A PE SHY AS a es A RIS BATT PT WLEEE BTX-A 7. 5 ~ LOU AR 4S FALSE ACAI PE FA Fe 28 VT > AB A FeO BA EAL. 3. ABLE LER a Ee indichotierlel iets PAL BEA NL eh A AP IM RE A 8 PF hE BT A FEA o UF neni EAM Ay FAL it ‘i FUE HE AE PAT ST 5 EE hy EF HR AR — 4S 9 HE DLA A HA ea WL AS Sb YR BY SE BE IDLY 5 ik PED it DAE FAVA REECE FEB FRAT HE AS — VCE — fl, WEY 2 J] Jee TEAS RTE ST 5 — A SLRS 95 — OU PF A I WHE we